Mar 14, 2019 / NTS GMT
Isao Teshirogi - Shionogi & Co., Ltd. - CEO, President & Representative Director
Thank you for joining our annual R&D presentation. Materials we have been preparing for the presentations are evolving. And this time, it exceeded 150 pages. There may be some pages that are not necessary for you, but it encompasses a full year summary of research and development. And today, we announced what we will develop in the next fiscal year. I appreciate your kind understanding.
In summary, we always aspire to achieve more in our R&D activities. We believe and discuss we can do more and faster. In the context of the industry trend and peers in the industry, we have made a fair progress versus the plan we announced in last year. I rarely speak highly of our R&D, but I see good results being delivered from R&D.
How R&D can lead the company in preparing our pipeline after Dortegravir and Xofluza in 2020 and after? As you see here, 7 projects plus 1, 8 projects in total as we added S-812217. These are the high-priority projects. Today, we touch on more details on pain/CNS about
Shionogi & Co Ltd R&D Meeting Transcript
Feb 14, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers